These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 32379713

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of Lactic Acid Bacteria Isolated from Fermented Plant Products for Antagonistic Activity Against Urinary Tract Pathogen Staphylococcus saprophyticus.
    Tsai CC, Lai TM, Lin PP, Hsieh YM.
    Probiotics Antimicrob Proteins; 2018 Jun; 10(2):210-217. PubMed ID: 28780720
    [Abstract] [Full Text] [Related]

  • 3. Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infection in a mouse model.
    Fraga M, Scavone P, Zunino P.
    Antonie Van Leeuwenhoek; 2005 Jul; 88(1):25-34. PubMed ID: 15928974
    [Abstract] [Full Text] [Related]

  • 4. Potential Probiotics Bacillus subtilis KATMIRA1933 and Bacillus amyloliquefaciens B-1895 Co-Aggregate with Clinical Isolates of Proteus mirabilis and Prevent Biofilm Formation.
    Algburi A, Alazzawi SA, Al-Ezzy AIA, Weeks R, Chistyakov V, Chikindas ML.
    Probiotics Antimicrob Proteins; 2020 Dec; 12(4):1471-1483. PubMed ID: 31989448
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Vaccination to Protect Against Proteus mirabilis Challenge Utilizing the Ascending Model of Urinary Tract Infection.
    Smith SN, Himpsl SD, Mobley HLT.
    Methods Mol Biol; 2019 Dec; 2021():201-215. PubMed ID: 31309507
    [Abstract] [Full Text] [Related]

  • 9. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.
    Li X, Lockatell CV, Johnson DE, Lane MC, Warren JW, Mobley HL.
    Infect Immun; 2004 Jan; 72(1):66-75. PubMed ID: 14688082
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Adherence of Proteus mirabilis to Uroepithelial Cells.
    González MJ, Iribarnegaray V, Scavone P, Zunino P.
    Methods Mol Biol; 2019 Jan; 2021():129-137. PubMed ID: 31309502
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vero cell invasiveness of Proteus mirabilis.
    Peerbooms PG, Verweij AM, MacLaren DM.
    Infect Immun; 1984 Mar; 43(3):1068-71. PubMed ID: 6365782
    [Abstract] [Full Text] [Related]

  • 17. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.
    Alamuri P, Eaton KA, Himpsl SD, Smith SN, Mobley HL.
    Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Phage Cocktail To Control Surface Colonization by Proteus mirabilis in Catheter-Associated Urinary Tract Infections.
    Mirzaei A, Wagemans J, Nasr Esfahani B, Lavigne R, Moghim S.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0209222. PubMed ID: 36194151
    [Abstract] [Full Text] [Related]

  • 20. Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins.
    Scavone P, Sosa V, Pellegrino R, Galvalisi U, Zunino P.
    Microbes Infect; 2004 Jul 26; 6(9):853-60. PubMed ID: 15374007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.